Syn2bio shares halted at Warsaw Stock Exchange debut
15/04/2026 09:26
April 15 (Reuters) - Shares of Polish pharmaceutical firm Syn2bio S2BP.WA, spun off from medical equipment maker Synektik SNTP.WA, failed to open on their expected Warsaw Stock Exchange debut on Wednesday. Syn2bio's main focus is in the development and commercialisation of its SYN2 cardiac tracer, a radiopharmaceutical compound for diagnosing coronary artery disease, targeting the U.S. market. At 0820 GMT, the theoretical opening price was at 47.6 zlotys, but the shares remained halted due to issues with establishing the actual price The separation from Synektik was aimed at unlocking new funding sources for the project and allowing investors to better value the companies' business profiles After the split, Synektik will no longer bear the research costs for SYN2, about 20-30 million zlotys ($5.6 million-$8.3 million) annually That should boost Synektik's own profitability and dividend potential Synektik will now focus on its core business, distributing medical devices such as its flagship da Vinci surgical robotic systems ($1 = 3.5953 zlotys) (Reporting by Alicja Surdy, additional reporting by Julia Zmarzlik, editing by Milla Nissi-Prussak) ((AlicjaEwa.Surdy2@thomsonreuters.com;))